Session: 621. Lymphomas: Translational – Molecular and Genetic: Poster II
Hematology Disease Topics & Pathways:
Research, Translational Research, Lymphomas, B Cell lymphoma, Plasma Cell Disorders, Genomics, Diseases, Lymphoid Malignancies, Biological Processes
Treatment of WM patients’ mononuclear cells with WNK463, a commercially available potent and selective oral kinase inhibitor of the four WNK kinase family members (WNK1-WNK4), induced a dose-dependent B-cell death. Taken together, our findings demonstrated novel and cancer-specific isoforms of WNK2, highly expressed in WM and aggressive cholangiocarcinoma tumors, of which the dominant S-NK isoform in WM promotes inflammation and myeloid chemotaxis. Our findings provide a critical framework for the selective therapeutic targeting of cancer-specific WNK2 isoforms.
Disclosures: Castillo: AbbVie: Consultancy, Research Funding; AstraZeneca: Consultancy, Research Funding; Cellectar Biosciences: Consultancy, Research Funding; Pharmacyclics: Consultancy, Research Funding; LOXO: Consultancy, Research Funding; Janssen: Consultancy; Kite Pharmaceuticals: Consultancy; Mustang Bio: Consultancy; BeiGene: Consultancy, Research Funding. Sarosiek: BeiGene: Honoraria, Research Funding; Cellectar Biosciences: Honoraria, Research Funding; ADC Therapeutics: Research Funding. Branagan: Adapative: Consultancy, Research Funding; BeiGene: Consultancy, Research Funding; CSL Behring: Consultancy, Research Funding; Genzyme: Consultancy, Research Funding; Karyopharm: Consultancy, Research Funding; Pharmacyclics: Consultancy, Research Funding; Sanofi: Consultancy, Research Funding. Anderson: Genentech: Consultancy; Amgen: Consultancy; Window: Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Consultancy; Pfizer: Consultancy; Janssen: Consultancy; Dynamic Cell Therapies: Membership on an entity's Board of Directors or advisory committees; C4 Therapeutics: Membership on an entity's Board of Directors or advisory committees; Starton Therapeutics: Membership on an entity's Board of Directors or advisory committees. Munshi: Oncopep: Current holder of stock options in a privately-held company; AbbVie, Adaptive Bio, Amgen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Karyopharm, Legend Bio, Novartis, Oncopep, Pfizer, Recordati, Sebia, Takeda: Consultancy. Treon: AbbVie/Pharmacyclics: Honoraria, Research Funding; BeiGene, Inc.: Honoraria, Research Funding; Eli Lilly: Research Funding; Janssen: Honoraria, Research Funding; Parexel: Honoraria, Research Funding.
See more of: Oral and Poster Abstracts